1.Pfaller, MA, Jones, RN, Messer, SA, Edmond, MB, Wenzel, RP, SCOPE Participant Group. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998;30:121–129.
2.Beck-Sague, C, Jarvis, WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990: National Nosocomial Infections Surveillance System. J Infect Dis 1993;167:1247–1251.
3.Chen, YC, Chang, SC, Sun, CC, Yang, LS, Hsieh, WC, Luh, KT. Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in Taiwan, 1981 to 1993. Infect Contrat Hosp Epidemiol 1997;18:369–375.
4.Hung, CC, Chen, YC, Chang, SC, Luh, KT, Hsieh, WC. Nosocomial candidemia in a university hospital in Taiwan. J Formos Med Assoc 1996;95:19–28.
5.White, TC, Marr, KA, Bowden, RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998;11:382–402.
6.Vanden Bossche, H, Marichal, P, Odds, FC. Molecular mechanisms of drug resistance in fungi. Trends Microbiol 1994;2:393–400.
7.Law, D, Moore, CB, Wardle, HM, Ganguli, LA, Keaney, MG, Denning, DW. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother 1994;34:659–668.
8.Patel, R, Portela, D, Badley, AD, et al.Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996;62:926–934.
9.Hadfield, TL, Smith, MB, Winn, RE, Rinaldi, MG, Guerra, C. Mycoses caused by Candida lusitaniae. Rev Infect Dis 1987;9:1006–1012.
10.Orozco, AS, Higginbotham, LM, Hitchcock, CA, et al.Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998;42:2645–2649.
11.Piemonte, P, Conte, G, Flores, C, et al.Emergence of fluconazole-resistant infections by Candida krusei and Candida glabrata in neutropenic patients. Rev Med Chil 1996;124:1149.
12.Akova, M, Akalin, HE, Uzun, O, Gur, D. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis 1991;10:598–599.
13.Prasad, KN, Agarwal, J, Dixit, AK, Tiwari, DP, Dhole, TN, Ayyagari, A. Róle of yeasts as nosocomial pathogens and their susceptibility to fluconazole and amphotericin B. Indian J Med Res 1999;110:11–17.
14.Pfaller, MA, Jones, RN, Doern, GV, et al.Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000;44:747–751.
15.Wingard, JR, Merz, WG, Saral, R. Candida tropicalis: a major pathogen in immunocompromised patients. Ann Intern Med 1979;91:539–543.
16.Graybill, JR, Najvar, LK, Holmberg, JD, Luther, MF. Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice. Antimicrob Agents Chemother 1995;39:924–929.
17.Barchiesi, F, Calabrese, D, Sanglard, D, et al.Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob Agents Chemother 2000;44:1578–1584.
18.Baran, J Jr, Klauber, E, Barczak, J, Riederer, K, Khatib, R. Trends in antifungal susceptibility among Candida sp. urinary isolates from 1994 and 1998. J Clin Microbiol 2000;38:870–871.
19.St. Germain, G, Laverdiere, M, Pelletier, R, et al.Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 2001;39:949–953.
20.Jandourek, A, Brown, P, Vazquez, JA. Community-acquired fungemia due to a multiple-azole-resistant strain of Candida tropicalis. Clin Infect Dis 1999;29:1583–1584.
21.Magaldi, S, Mata, S, Hartung, C, et al.In vitro susceptibility of 137 Candida sp. isolates from HIV positive patients to several antifungal drugs. Mycopathologia 2001;149:63–68.
22.Lo, H-J, Ho, AH, Ho, M. Factors accounting for mid-identification of Candida species. J Microbiol Immunol Infect 2001;34:171–177.
23.National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Wayne, PA: National Committee for Clinical Laboratory Standards; 1997. Approved standard M27.
24.Dean, AG, Dean, JA. Epi Info (6.04): A Word Processing, Database, and Statistics Program for Epidemiology on Microcomputers. Atlanta: Centers for Disease Control and Prevention; 1996.
25.Hitchcock, CA. Cytochrome P-450-dependent 14 alpha-sterol demethylase of Candida albicans and its interaction with azole antifungals. Biochem Soc Trans 1991;19:782–787.
26.Vanden Bossche, H, Warnock, DW, Dupont, B, et al.Mechanisms and clinical impact of antifungal drug resistance. Journal of Medical and Veterinary Mycology 1994;32(suppl 1):189–202.
27.Abi-Said, D, Anaissie, E, Uzun, O, Raad, I, Pinzcowski, H, Vartivarian, S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24:1122–1128.
28.Slavin, MA, Osborne, B, Adams, R, et al.Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545–1552.
29.Walsh, TJ, Hiemenz, JW, Seibel, NL, et al.Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383–1396.
30.Safdar, A, Chaturvedi, V, Cross, EW, et al.Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother 2001;45:2129–2133.
31.Calvet, HM, Yeaman, MR, Filler, SG. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob Agents Chemother 1997;41:535–539.